|Day Low/High||79.12 / 80.49|
|52 Wk Low/High||73.69 / 89.09|
Do we trade on the news out of Washington? Jim Cramer talks about Larry Kudlow and his stand on economic growth.
The Indianapolis-based drugmaker launched Verzenio in October.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ABEV, APU, EBR, FNCB, TROW Downgrades: BSX, HLF, IROQ, KR, KWR, LABL, LLY, NX Initiations: AQN Read on to get TheStreet Quant Ratings' detailed report:
EMPERIAL clinical trials will evaluate the effect of Jardiance (empagliflozin) on exercise ability and heart failure symptoms in people with chronic heart failure
The price of LLY has climbed and the bearish price target on the Point and Figure chart is off the table.
Consider this LLY bullishly biased vertical call spread expiring in June.
Initiations/Exits, Price Target Updates and Ratings Changes are all here.
- Migraine Impact Report highlights physical, social and economic challenges of migraine -
- Reductions in the impact of genital psoriasis on sexual activity seen as early as one week -
We could be poised for even a further advance PROVIDED that we stay oversold.
- 14 abstracts include data for Taltz in genital psoriasis, baricitinib in atopic dermatitis and mirikizumab in plaque psoriasis -
Consider this LLY out of the money, bullishly biased vertical call spread expiring in April.
We are essentially buying back the shares we recently sold -- at a large discount.
While Donald Trump's tweets can shake up pharmaceutical stocks, history suggests that investors have little to fear from the president's drug pricing rhetoric.
Nothing has changed with fundamentals, so 'good names' have gone on sale.
'I think everybody is looking at potential combinations and consolidations,' Pfizer CEO Ian Read said on an earnings call on Tuesday, Jan. 30.
In a special edition of Mad money, Jim Cramer examines this brutal decline and lays out the game plan for next week -- live from Minneapolis ahead of the Super Bowl.
Jim Cramer highlights Shopify, Kinder Morgan, Thermo Fisher Scientific, Radius Health, Merck, Pfizer and more.
Jim Cramer explains how to rely on long-term themes to take advantage of this market's wild action.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.